TECHNOLOGY FOCUS - BIOTECHNOLOGY - Recombinant Methods (Disclosed): The recombinant microorganism (m1) and (m2) is prepared by the standard recombinant techniques. Preferred Components: The microorganism has at least 15% less nucleosome histone acetyltransferases (HAT) activity in at least one of a NuA4 and piccolo NuA4 complex than a wild type microorganism. The microorganism has at least 15% greater translation of a galactose regulated gene product than a wild type microorganism. The modified YNG2 comprises a deletion of a homeodomain (PHD)-finger domain. The deletion comprises residues 220-282 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105). The modified YNG2 comprises at least one amino acid substitution at a position selected from positions corresponding to positions 227, 235, 243, 252, and 264 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); at least one amino acid substitution at positions selected from positions corresponding to positions 221-282, 254-282, and 264-282 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); at least one amino acid substitution at a position selected from positions corresponding to positions 40, 54, 60, 61, 91, 103, 129, 133, 134, 147, and 182 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); an amino acid sequence selected from (SEQ ID NO: 90), (SEQ ID NO: 92), (SEQ ID NO: 106), (SEQ ID NO: 107), (SEQ ID NO: 108), (SEQ ID NO: 109), and (SEQ ID NO: 110) available on WIPO website; an amino acid sequence comprising a cysteine to tyrosine substitution (Cys227Tyr mutation) at a position corresponding to position 227 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); an amino acid sequence comprising a methionine to isoleucine substitution (Met235Ile mutation) at a position corresponding to position 235 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); an amino acid sequence comprising a cysteine to arginine substitution (Cys243Arg mutation) at a position corresponding to position 243 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); an amino acid sequence comprising a cysteine to tyrosine substitution (Cys252Tyr mutation) at a position corresponding to position 252 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); amino acid sequence comprising a tyrosine to histidine substitution (Tyr264His mutation) at a position corresponding to position 264 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); amino acid sequence comprising a lysine to arginine substitution (Lys40Arg mutation) at a position corresponding to position 40 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); amino acid sequence comprising an arginine to glycine substitution (Arg54Gly mutation) at a position corresponding to position 54 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); amino acid sequence comprising a proline to serine substitution (Pro60Ser mutation) at a position corresponding to position 60 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); amino acid sequence comprising a lysine to arginine substitution (Lys61Arg mutation) at a position corresponding to position 61 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); amino acid sequence comprising an asparagine to serine substitution (Asn91Ser mutation) at a position corresponding to position 91 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); amino acid sequence comprising a lysine to arginine substitution (Lys103Arg mutation) at a position corresponding to position 103 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); amino acid sequence comprising an alanine to serine substitution (Ala129Ser mutation) at a position corresponding to position 129 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); amino acid sequence comprising a serine to tyrosine substitution (Ser133Tyr mutation) at a corresponding to position 133 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); amino acid sequence comprising an arginine to serine substitution (Arg134Ser mutation) at a position corresponding to position 134 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); amino acid sequence comprising an arginine to lysine substitution (Arg147Lys mutation) at a position corresponding to position 147 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); amino acid sequence comprising a lysine to arginine substitution (Lys182Arg mutation) at a position corresponding to position 182 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); amino acid sequence comprising a deletion of residues corresponding to residues 264-282 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); amino acid sequence comprising a deletion of residues corresponding to residues 254-282 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); amino acid sequence comprising a deletion of residues corresponding to residues 221-282 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); amino acid sequence comprising a deletion of residues corresponding to residues 181-282 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); amino acid sequence comprising a deletion of residues corresponding to residues 167-282 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); amino acid sequence comprising a deletion of residues corresponding to residues 111-282 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); amino acid sequence comprising a deletion of residues corresponding to residues 106-282 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); amino acid sequence comprising a deletion of residues corresponding to residues 181-219 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); amino acid sequence comprising a deletion of residues corresponding to residues 167-219 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); amino acid sequence comprising a deletion of residues corresponding to residues 111-219 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105); amino acid sequence comprising a deletion of residues corresponding to residues 106-219 of the wild-type YNG2p amino acid sequence (SEQ ID NO: 105). The recombinant microorganism further comprises an isoprenoid pathway enzyme to form an isoprenoid product; heterologous nucleic acid encoding an enzyme that modifies a polyprenyl to form product selected from hemiterpene, monoterpene, sesquiterpene, diterpene, triterpene, tetraterpene, polyterpene, steroid compound, carotenoid, and modified acetyl-CoA derived compound; heterologous nucleic acid encoding at least one polyketide synthesis enzyme; heterologous nucleic acid encoding at least one fatty acid synthesis enzyme. The isoprenoid pathway enzyme is selected from enzyme that condenses two molecules of acetyl-coenzyme A to form acetoacetyl-CoA; enzyme that condenses acetoacetyl-CoA with another molecule of acetyl-CoA to form 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA); enzyme that converts HMG-CoA into mevalonate; enzyme that converts mevalonate into mevalonate 5-phosphate; enzyme that converts mevalonate 5-phosphate into mevalonate 5-pyrophosphate; enzyme that converts mevalonate 5-pyrophosphate into isopentenyl diphosphate (IPP); enzyme that converts IPP into dimethylallyl pyrophosphate (DMAPP); polyprenyl synthase that can condense IPP and/or DMAPP molecules to form polyprenyl compounds containing more than five carbons; enzyme that condenses IPP with DMAPP to form geranyl pyrophosphate (GPP); enzyme that condenses two molecules of IPP with one molecule of DMAPP; enzyme that condenses IPP with GPP to form farnesyl pyrophosphate (FPP); enzyme that condenses IPP and DMAPP to form geranylgeranyl pyrophosphate (GGPP); and, enzyme that condenses IPP and FPP to form GGPP. The heterologous nucleic acid encoding an enzyme that modifies a polyprenyl is selected from geraniol synthase, linalool synthase, limonene synthase, myrcene synthase, ocimene synthase, alpha -pinene synthase, beta -pinene synthase, sabinene synthase, gamma -terpinene synthase, terpinolene synthase, amorphadiene synthase, alpha -farnesene synthase, beta -farnesene synthase, farnesol synthase, nerolidol synthase, patchouliol synthase, nootkatone synthase, or abietadiene synthase. The polyketide synthesis enzyme is selected from: enzyme that condenses at least one of acetyl-CoA and malonyl-CoA with an acyl carrier protein; enzyme that condenses a first reactant selected from acetyl-CoA and malonyl-CoA with a second reactant selected from malonyl-CoA or methylmalonyl-CoA to form a polyketide product; enzyme that reduces a beta -keto chemical group on a polyketide compound to a beta -hydroxy group; enzyme that dehydrates alkane chemical group in a polyketide compound to produce an alpha , beta -unsaturated alkene; enzyme that reduces an alpha , beta -double-bond in a polyketide compound to a saturated alkane; and enzyme that hydrolyzes a polyketide compound from an acyl carrier protein. The fatty acid synthesis enzyme is selected from an enzyme that covalently links at least one of acetyl-CoA and malonyl-CoA to acyl carrier protein (ACP); enzyme that condenses acetyl-ACP and malonyl-ACP to form acetoacetyl-ACP; reduce the double bond in acetoacetyl-ACP with nicotineadenine dinucleotide hydrogen phosphate (NADPH) to form a hydroxyl group in D-3-hydroxybutyryl hydroxylase-ACP; an enzyme that dehydrates D-3-hydroxybutyryl hydroxylase-ACP to create a double bond between the beta- and gamma-carbons forming crotonyl-ACP; an enzyme that reduces crotonyl ACP with NADPH to form butyryl-ACP; and, enzyme that hydrolyzes a 16C acyl compound from an acyl carrier protein to form palmitate. The heterologous nucleic acid molecules are comprised on one heterologous nucleic acid molecule; are comprised on several heterologous nucleic acid molecules; are under inducible control; are integrated into a chromosome; are on a plasmid. Each heterologous nucleic acid encodes a eukaryotic enzyme; encodes a yeast enzyme; encodes a eukaryotic enzyme. The vector is an expression vector where the nucleic acid molecule is operably linked to at least one control sequence allowing the expression of the nucleic acid molecule in host cells. The control sequences are GAL promoters. The nucleic acid molecule is selected from a nucleic acid molecule given in a sequence selected from (SEQ ID NO: 100), (SEQ ID NO: 101), (SEQ ID NO: 102) and (SEQ ID NO: 103) available on WIPO website. Preferred Microorganism: The recombinant microorganism is a prokaryote (preferably Escherichia coli); eukaryote (preferably fungi or Yeast which belongs to the genera selected from Aciculoconidium, Ambrosiozyma, Arthroascus, Arxiozyma, Ashbya, Babjevia, Bensingtonia, Botryoascus, Botryozyma, Brettanomyces, Bullera, Bulleromyces, Candida, Citeromyces, Clavispora, Cryptococcus, Cystofilobasidium, Debaryomyces, Dekkara, Dipodascopsis, Dipodascus, Eeniella, Endomycopsella, Eremascus, Eremothecium, Erythrobasidium, Fellomyces, Filobasidium, Galactomyces, Geotrichum, Guilliermondella, Hanseniaspora, Hansenula, Hasegawaea, Holtermannia, Hormoascus, Hyphopichia, Issatchenkia, Kloeckera, Kloeckeraspora, Kluyveromyces, Kondoa, Kuraishia, Kurtzmanomyces, Leucosporidium, Lipomyces, Lodderomyces, Malassezia, Metschnikowia, Mrakia, Myxozyma, Nadsonia, Nakazawaea, Nematospora, Ogataea, Oosporidium, Pachysolen, Phachytichospora, Phaffia, Pichia, Rhodosporidium, Rhodotorula, Saccharomyces, Saccharomycodes, Saccharomycopsis, Saitoella, Sakaguchia, Saturnospora, Schizoblastosporion, Schizosaccharomyces, Schwanniomyces, Sporidiobolus, Sporobolomyces, Sporopachydermia, Stephanoascus, Sterigmatomyces, Sterigmatosporidium, Symbiotaphrina, Sympodiomyces, Sympodiomycopsis, Torulaspora, Trichosporiella, Trichosporon, Trigonopsis, Tsuchiyaea, Udeniomyces, Waltomyces, Wickerhamia, Wickerhamiella, Williopsis, Yamadazyma, Yarrowia, Zygoascus, Zygosaccharomyces, Zygowilliopsis, and Zygozyma); is selected from Saccharomyces cerevisiae, Pichia pastoris, Schizosaccharomyces pombe, Dekkera bruxellensis, Kluyveromyces lactis (previously called Saccharomyces lactis), Kluveromyces marxianus, Arxula adeninivorans, and Hansenula polymorpha (now known as Pichia angusta)); Candida lipolytica, Candida guilliermondii, Candida krusei, Candida pseudotropicalis, and Candida utilis; Saccharomyces cerevisiae; strain of Saccharomyces cerevisiae selected from Baker's yeast, CBS 7959, CBS 7960, CBS 7961, CBS 7962, CBS 7963, CBS 7964, IZ-1904, TA, BG-1, CR-1, SA-1, M-26, Y-904, PE-2, PE-5, VR-1, BR-1, BR-2, ME-2, VR-2, MA-3, MA-4, CAT-1, CB-1, NR-1, BT-1, and AL-1; microalga; Chlorella or Prototheca).    TECHNOLOGY FOCUS - ORGANIC CHEMISTRY - Preferred Components: The cyclic lactone is one of a 14, 15, or 16-membered ring.    TECHNOLOGY FOCUS - PHARMACEUTICALS - Preferred Components: The polyketide product is a lipid having at least one of antibiotic, antifungal, and antitumor activity (preferably macrolid, antibiotic, antifungal, cytostatic compound, anticholesterolemic compound, antiparasitic compound, coccidiostatic compound, animal growth promoter and insecticide); polyene; and cyclic lactone. ACTIVITY - None given.    MECHANISM OF ACTION - None given.    EXAMPLE - No suitable example given.